HAPILA and Transo-Pharm cement partnership with joint synthesis announcement at CPHI Frankfurt 2025

10/17/2025

[Translate to English:] — Combined HAPILA and Transo-Pharm Handels-GmbH team: (L-R) Frank Krause (Managing Director Transo-Pharm), Timo Krabiell (Transo-Pharm), Dr. Uwe Müller (Managing Director HAPILA GmbH), Jessica Ha (Transo-Pharm), Dr. Richard Nohl (HAPILA), Dr. Steffen Wittmann (HAPILA), Geng Xiding (Transo-Pharm)

The strategic partnership between high-potency active ingredient specialist CDMO HAPILA GmbH and global marketing and distribution partner Transo-Pharm Handels-GmbH, will be again present at their shared stand (Booth C80, Hall 11.0, API Zone) at Messe Frankfurt during the CPHI Worldwide (October28th-30th). Strengthening their collaboration, the stand will feature details of the commissioning of a new GMP plant at HAPILA’s Thuringia site for the commercial-scale production of API to fulfill all customers current and prospective expectations regarding quality and quantity “Made in Germany”. The facility has now come online in September 2025.

Back